Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00311012 |
This study will evaluate the efficacy of SPP100 in lowering blood pressure in patients with essential hypertension.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Aliskiren |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Dose-Finding Study of SPP100 in Essential Hypertension |
Estimated Enrollment: | 440 |
Study Start Date: | August 2004 |
Estimated Study Completion Date: | March 2005 |
Ages Eligible for Study: | 20 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CSPP100A1201 |
Study First Received: | March 31, 2006 |
Last Updated: | June 1, 2006 |
ClinicalTrials.gov Identifier: | NCT00311012 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Hypertension, Aliskiren |
Signs and Symptoms Essential Hypertension Vascular Diseases Hypertension |
Vascular Diseases Cardiovascular Diseases Hypertension |